Bringing the fundamentals into focus…
Back to ANI Pharmaceuticals, Inc.
How ANI Pharmaceuticals, Inc. stacks up
ANIP · against 440 other Healthcare companies of similar size
Valuation
89/ 100
Near the top of its peers.
Ranked #47 of 441 · scores higher than 89% of peers
Bars: peers in each 10-point band of the valuation score59 peers with a valuation score of 80–89, including ANIP · Click a bar to see the companies
Why valuation scores 89?
Weighted metrics compared with all Healthcare companies.Mainly thanks to its free cash flow yield, earnings yield and EBITDA yield, which are stronger than most Healthcare peers.
- more operating profit (EBITDA) for the company's total value: stronger than 85% of peers. EBITDA yield: 15.5% vs peer median 4.0%
- higher earnings for the price paid: stronger than 86% of peers. Earnings yield: 6.8% vs peer median 1.5%
- more free cash flow for the price paid: stronger than 93% of peers. Free cash flow yield: 10.9% vs peer median 0.0%
Metric by metric
Position: dot = ANIP, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | ANIP | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 429 reported | 6.4% | 1.5% | 85% | 30% | |
| EBITDA yieldHigher is better · 441 reported | 11.6% | 4.3% | 85% | 50% | |
| Free cash flow yieldHigher is better · 200 reported | 10.1% | -0.5% | 92% | 20% | |
| Book yieldHigher is better · 431 reported | 38.6% | 36.9% | 52% | Context only |
Ranking by valuation score
Top 5 and the companies ranked around ANIPScores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score